KR20140018458A - Composition for preventing and treating bacterial prostatitis comprising hot spring water - Google Patents

Abstract

The present invention relates to a composition for preventing, treating, and curing bacterial prostatitis containing hot spring water as an effective component. The present invention also relates to a composition for preventing, treating, and curing bacterial prostatitis containing hot spring water and ciprofloxacin. The hot spring water contains potassium, selenium, lithium, sodium, vanadium, chlorine ions, calcium, germanium, fluorine, magnesium, manganese, bromine, iron, cobalt, sulfuric acid, zinc, titanium, and boron.

Description

TECHNICAL FIELD The present invention relates to a composition for preventing and treating bacterial prostatitis including hot spring water,

The present invention relates to a composition for preventing, treating or ameliorating bacterial prostatitis comprising hot spring water as an effective ingredient. The present invention also relates to a composition for preventing, treating or ameliorating bacterial prostatitis including hot spring water and ciprofloxacin.

Chronic bacterial prostatitis (CBP) is the most common cause of urinary tract infection (UTI) in men and the social and economic costs of patients suffering from it are increasing each year. Chronic bacterial prostatitis is characterized by persistent pathogenic bacteria in the prostate gland and antibiotic treatment is the best treatment. However, the causes and pathologic mechanisms are so diverse that it is difficult for urologists and patients to diagnose and treat them.

In order to treat chronic bacterial prostatitis, quinolone-based drugs have emerged as an excellent agent for penetration into the prostate tissue, but from a long-term point of view, the superiority of the therapeutic effect is not yet proven. In addition, bacterial pathogens have a very low persistence of efficacy because they coagulate into micro-microorganisms to protect themselves from antibiotics or form biofilms locally on the affected prostate glands.

Recently, in order to overcome the limitation of antibiotics, interest in natural medicine such as combination therapy, diet or symptom therapy has been increasing in addition to antibiotic drug therapy.

On the other hand, hot spring water refers to water containing a certain amount of mineral component, water vapor, gas and the like at a temperature of 25 ° C or higher at the place where water is spouted. It is classified into sulfur spring, carbonate spring and salt spring spring depending on the chemical composition. Sulfur-based sulfur, which is mainly composed of sulfur, is known to have an effect on gastrointestinal diseases, and a carbonate spring containing iron is known to be effective for digestive diseases and anemia. Also, it is known that a salt spring containing a large amount of salt is effective for chronic dermatitis. Korean Patent Publication No. 0135716 discloses an oral composition including hot spring water, Korean Patent Laid-Open Publication No. 1995-0023399 discloses a cosmetic composition containing hot spring water, and Korean Patent Publication No. 2005-0120074 discloses an atopic Dermatitis treatments and so on.

The present inventors confirmed the effect of treatment of bacterial prostatitis in hot spring water in an animal model of chronic bacterial prostatitis. In addition, by evaluating the synergistic effect when hot spring water is administered together with an antibiotic, the hot spring water can be usefully used as a therapeutic agent or an adjuvant treatment for bacterial prostatitis. And completed the present invention.

It is an object of the present invention to provide a pharmaceutical composition for preventing or treating bacterial prostatitis comprising hot spring water.

It is another object of the present invention to provide a pharmaceutical composition for the prevention or treatment of bacterial prostatitis including hot spring water and ciprofloxacin.

In one aspect, the invention relates to a pharmaceutical composition for the prevention or treatment of bacterial prostatitis comprising hot spring water.

In another aspect, the present invention relates to a pharmaceutical composition for the prevention or treatment of bacterial prostatitis comprising hot spring water and ciprofloxacin.

Preferably, the compositions of the present invention are effective for preventing, treating and improving bacterial prostatitis, especially chronic bacterial prostatitis.

Hereinafter, the present invention will be described in more detail.

In the present invention, a hot spring water refers to a mineral mixture which is eluted from underground and whose constituents are not harmful to the human body and which is eluted from an underground rock layer of a coastal hot spring area, It can be a hot spring water containing high concentration.

In general, seawater is called seawater deep sea water by distinguishing it from surface seawater. Seaweed deep seawater refers to seawater less than 200 meters from the surface of seawater. It does not cause photosynthesis, and it contains many nutrients such as nitrogen, phosphorus and silicate And it is known that it is not polluted by air or chemical substances, and is not contaminated by solar or general bacteria, and has a good physical cleanliness due to a small number of positive bacteria.

In addition, it has a low water temperature change at low temperature throughout the year, has a stable low water temperature, and contains essential trace elements and various minerals in a balanced manner, so that the effect of dissolved ions on the active oxygen is excellent in the body .

Therefore, the surface water is not suitable for use in the human body such as food and beverages in the present state of severe marine pollution. However, since deep sea water is not much in number in the surface layer and contains almost no pathogenic organisms, It can be said that the safety is extremely high.

The inventors of the present invention found that marine mineral water, which is a deep ocean water eluting from the 1100 m underground of a hot spring area in coastal monotone region, 92-1, Kangjin 3 ridge, Okgye-myeon, Gangneung-myeon, Gangwon-do, Republic of Korea is a bacterial prostatitis, especially chronic bacterial prostatitis And the effect of prevention, treatment, and improvement of the disease was confirmed.

Accordingly, in the present invention, the hot spring water may be a marine mineral water taken at a location 1100 m underground of a hot spring area in the coastal monotonous area of 92-1, Kejin 3 rye, Okgye-myeon, Gangneung-do, Gangwon-do, Korea.

Preferably, in the present invention, the hot spring water may be one containing potassium, selenium, lithium, sodium, vanadium, chlorine ion, calcium, germanium, fluorine, magnesium, manganese, bromine, iron, cobalt, sulfuric acid, zinc, have. More preferably, the hot spring water is selected from the group consisting of potassium 180-230 mg / L, selenium 200-500 ug / L, lithium 0.02-0.15 mg / L, sodium 7000-9500 mg / L, vanadium 65-130 / / L of germanium, 1.5 to 3.0 mg / L of fluorine, 900 to 1100 mg / L of magnesium, 10 to 40 g / L of manganese, 40 to 60 g / L of zinc, 1.0 to 3.0 mg / L of iron, 1 to 3.5 μg / L of cobalt, 3000 to 5000 mg / L of sulfuric acid ions, 3.0 to 10.0 mg / L of zinc, 0.5 to 1.5 mg of boron / L. ≪ / RTI >

These components were confirmed by KIST (Korea Institute of Science and Technology) and KBSI (Korea Basic Science Institute) with component analysis.

In the present invention, the hot spring water can be used as it is or can be processed and used, for example, as a solid crystal obtained by evaporation, concentration and drying. Alternatively, a concentrate obtained by evaporating the natural hot water or by artificially desalting and drying (or evaporating) the hot water can be used. The method of evaporation, concentration and drying is not particularly limited, but can be obtained, for example, by evaporating underground hot spring water into primary, secondary and tertiary evaporators, filtering and concentrating and drying.

In an embodiment of the present invention, when the hot spring water itself is used, it may be used in an amount of 50% (v / v) to 100% (v / v) based on the total weight of the composition, May be used in an amount of 0.5 to 50% (v / v) based on the total weight of the composition.

In one specific embodiment, the concentrate of the hot spring water according to the present invention can be prepared as follows. First, the raw water is collected and then subjected to a filtration step for filtering. In this case, the filtration step may be performed through several filtration steps. In the specific embodiment of the present invention, the filtration step is performed in four steps. That is, the first step filtration was performed by removing the suspended matters having a particle size of more than 10 μm. Then, the suspended matters having a particle size of more than 5 μm were filtered out and then filtered. After sterilization by UV, the suspension of more than 0.2um was filtered out by a four step filtration process. The thus-obtained filtrate can be subjected to a desalting step and a drying step, and desalting is not limited thereto, but an electrodialyzer can be used.

Thereafter, the desalted powder can be produced through natural drying or drying using a dry dryer. In one embodiment of the present invention, a vacuum freeze dryer was used for the drying. In the final step, desalination powder can be pulverized and packaged.

In addition, the concentrate of the hot spring water according to the present invention can be concentrated by first collecting the raw water, drying it, and then performing the filtration step.

Preferably, the prostatitis in the present invention may be a bacterial prostatitis, more preferably a chronic bacterial prostatitis.

Bacterial prostatitis is a persistent pathogenic bacterium of the prostate as an inflammatory disease, and its clinical features are nonspecific, and the pathogenesis has yet to be elucidated. Bacterial prostatitis is not easy to treat because pathogenic bacteria are present in the prostate and can cause lower urinary tract infection including urethritis, and recurrences are common after treatment. Moreover, since there is a barrier between the blood and the prostate gland, antibiotics act as a major limiting factor for the entry into the prostate gland. Therefore, conventionally, a therapeutic regimen is used in which an antibiotic is continuously administered at a low dose, Prolonged use of antibiotics leads to side effects and bacterial resistance.

In order to overcome this problem, the present invention directly identified the effect of hot spring water on bacterial prostatitis through an animal model of chronic bacterial prostatitis, and evaluated the effect as an antibiotic adjuvant.

In a specific embodiment of the present invention, animal models were divided into four groups and administered the drug for 4 weeks; (N = 8), and (4) hot spring water plus ciprofloxacin (n = 8). In the control group (n = 8), ciprofloxacin group (n = 8), hot spring water group (n = 8) Next, bacterial suspension (Escherichia coli Z17 O2: K1; H-) was instilled into SD rats to induce chronic bacterial prostatitis. The results of prostate tissue and urine culture were analyzed and histological analysis of prostate was performed in each experimental group for 4 weeks.

As a result, significant decrease of bacterial growth and improvement of prostate inflammation state were observed in the ciprofloxacin alone group and the combination group of hot spring water and ciprofloxacin (p <0.05) as compared with the control group. In particular, the combined treatment group showed a significant decrease in bacterial growth and an improvement in the prostate inflammation state (p <0.05) compared to the case of fl iproxacin alone. The effect of reducing the number of bacteria in the hot spring water alone group compared to the control group was also confirmed.

These results indicate that hot spring water has a direct and significant therapeutic effect on bacterial prostatitis and synergistic effect when used in combination with antibiotics. Therefore, the inventors of the present invention for the first time have found that the use of hot spring water alone or in combination with ciprofloxacin can provide a useful effect for the treatment of bacterial prostatitis.

When the composition of the present invention is used as a pharmaceutical composition, the content of the hot spring water in the composition can be appropriately adjusted according to the symptom of the disease, the progress of symptoms, the condition of the patient and the like, for example, 0.0001 to 99.9% By weight, preferably 0.001 to 50% by weight, but is not limited thereto. The content ratio is a value based on the dried amount from which the solvent is removed.

The composition may further contain an appropriate carrier, excipient and diluent conventionally used in the production of a pharmaceutical composition. The composition may be administered orally or parenterally in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, An external preparation, a suppository or a sterilized injection solution, and the like.

When the composition is formulated, it is prepared using a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or an excipient usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations may include at least one excipient and / or lubricant. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration may include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, suppositories, and the like.

The preferred dosage of the composition varies depending on the condition and the weight of the patient, the degree of the disease, the drug form, the administration route and the period, but can be appropriately selected by those skilled in the art. For a more preferable effect, the dose of the composition of the present invention is preferably 0.1 mg / kg to 100 mg / kg per day based on the active ingredient, but is not limited thereto. The administration may be carried out once a day or divided into several doses. The compositions of the present invention may be administered to a mammal, including a human, in various ways. All modes of administration may be expected, for example, by oral, intravenous, intramuscular, subcutaneous injection, and the like. The pharmaceutical dosage form of the composition of the present invention may be used in the form of a pharmaceutically acceptable salt of the active ingredient, and may be used alone or in combination with other pharmaceutically active compounds as well as in a suitable combination.

The composition of the present invention may also be used in a form contained in food, in which case it may include acceptable food-aid additives and may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of functional foods .

In the present invention, the term &quot; food &quot; means a natural product or a processed product containing one or more nutrients, preferably a state of being able to be directly eaten through a certain processing step, , Health functional foods, beverages, food additives and beverage additives. Examples of the food include various foods, beverages, gums, tea, vitamin complex, and functional foods. In addition, in the present invention, the food may contain special nutritional foods (e.g., crude oil, spirits, infant food, etc.), meat products, fish products, tofu, jelly, noodles (Such as soy sauce, soybean paste, hot pepper paste, mixed sauce), sauces, confectionery (eg snacks), dairy products (eg fermented milk, cheese), other processed foods, kimchi, pickled foods But are not limited to, natural flavors (eg, ramen soup, etc.), vitamin complexes, alcoholic beverages, alcoholic beverages and other health supplement foods. The health functional food, beverage, food additive or beverage additive can be produced by a usual production method.

Further, in the food, the amount of the hot spring water may be 0.00001% to 50% by weight of the total food. When the food is a beverage, the amount of the hot spring water is preferably 0.001 g to 50 g based on 100 ml of the whole food, But the present invention is not limited thereto.

The present invention is the first to confirm that a hot spring water has a therapeutic effect on chronic bacterial prostatitis. It can be used as a therapeutic agent for bacterial prostatitis by using hot spring water alone or in combination with cisploxacin in hot spring water. It is possible.

Fig. 1 shows chronic inflammatory cell infiltration, fibrin change and severity score of interstitial fibrosis in each group, and the respective mean ± SD values are compared with those of the control group. * Represents p <0.05 compared to the control group, † represents p <0.05 compared to the ciprofloxacin treated group, and SD represents the standard deviation.
Figure 2 shows the results of H & E staining in prostate tissue sections 4 weeks after each treatment in an animal model of chronic bacterial prostatitis (Bar = 100 [mu] m). (A) is a control group, (B) is a ciprofloxacin treated group, (C) is a hot spring water treated group, and (D) shows a result of a hot spring water and ciprofloxacin combination treatment group.

Hereinafter, the present invention will be described in detail with reference to examples. However, the following examples are illustrative of the present invention, and the present invention is not limited by the following examples.

Example  1. Preparation of experimental material

1-1. Experimental animal

A total of 32 adult Sprague Dawley (SD) rats (ORIENT BIO, Seongnam, Korea), weighing 250-350 g, were used as experimental animals and given a one week acclimation period. The temperature and humidity of the breeding room were maintained at 22 ± 2 ℃ and 40 ~ 60%, respectively, and food and water were freely consumed. Experiments were conducted in accordance with the Guidelines for the Management and Use of Laboratory Animals and the Animal Ethics Committee.

1-2. Preparation of hot spring water

In order to collect hot spring water, the present inventors collected hot spring water taken from a 110m underground rocky area of Geumjinri beach coastal area of Gangneung, Gangneung-gu, Gangwon-do, and filtered using a 0.25 micrometer line filter to remove contaminants. : 5.5 to 7.5 V, electrode solution: 3% Na2SO4, CJTTS-2-10 ED, Creation Techno). After the desalination process was completed, the precipitate was filtered and dried using a vacuum freeze dryer (temperature: -40 to 30 ° C., degree of vacuum: 5 mTorr), and the thus prepared hot spring water concentrate of the present invention was used for further experiments . The amount of selenium in this experiment was 480 ug / L, which was higher than that of conventional hot spring water. In addition, minerals such as vanadium 110 ug / L, calcium 1520 mg / L and magnesium 990 mg / This was confirmed by requesting component analysis to KIST (Korea Institute of Science and Technology) and KBSI (Table 1).

ingredient mg / L ingredient ug / L ingredient mg / L Potassium (K) 201 Selenium (Se) 480 Lithium (Li) 0.089 Sodium (Na) 9070 Vanadium (V) 110 Chlorine ion (Cl ^- ) 19394 Calcium (Ca) 1520 Germanium (Ge) 1.4 Fluorine (F) 2.6 Magnesium (Mg) 990 Manganese (Mn) 11 Bromine (Br) 55.4 Iron (Fe) 2.3 Cobalt (Co) 2.8 Sulfate ion (So ₄ ^{2 -} ) 4402 Zinc (Zn) 8.46 Titanium (Ti) 620 Boron (B) 1.08

Example  2. Establishment of an animal model of chronic bacterial prostatitis

In a chronic bacterial prostatitis model using rats, 10 ⁸ CFU / ml of E. coli was injected into the urethra. E. coli ^{Z17 (O2: K1; H -} ) 37 for one night in the was used the strains prior to injection in the animals, kept in liquid nitrogen freezing 70 ℃ following, TSB (tryptic soy broth) of the culture medium in the incubator of 70 ℃ Lt; 0 &gt; C. Immediately prior to injection, TSB was quantitatively re-cultured to give 10 ⁸ CFU / ml of bacteria.

The animals were anaesthetized with ether, sterilized with 70% alcohol around the urethra, and sterilized polyethylene tubes were inserted into the urethra of the experimental animals. Using an insulin syringe, the E. coli ^{Z17 (O2: K1; H -} ) 0.2 ml (1X10 8 CFU / ml). After the injection of the suspension, the anesthesia was maintained for 1 hour in order to prevent the leakage of urine due to movement of the mice and to maintain sufficient time for the bacteria to penetrate into the prostate gland.

All animals were anesthetized with ketamine (50 mg / kg) and xylazine (12 mg / kg) at 4 weeks after injection of E. coli suspension for confirmation of the chronic bacterial prostatitis model. And the prostate was removed. Ventral prostate (VP) was selected and collected. Urine was collected by bladder catheterization and McConkey agar agar culture was performed. Microscopically, chronic bacterial prostatitis is characterized by infiltration of inflammatory cells, interstitial fibrosis, and fibrillar changes, so that each specimen meets chronic bacterial prostatitis histologically and the number of bacterial strains in culture is more than 20 CFU per gram of tissue Chronic bacterial prostatitis model was selected.

Example  3. Experimental group  And processing

A total of 32 SD rats were randomly assigned to the following four groups.

(1) Control group (n = 8): 1 ml of phosphate buffered saline (PBS, pH 7.2) was administered via an 8F red Rob-Nel catheter twice a day for 4 weeks.

(2) Ciprofloxacin-treated group (n = 8): 2.5 mg of ciprofloxacin (Cycin®, Ildong Pharm, Seoul, Korea) per 1 kg of body weight was diluted in 1 ml of distilled water and administered by the 8F red Rob-Nel catheter once a day for 4 weeks .

(3) Hot spring water treatment group (n = 8): Hot spring water was administered through an 8F red Rob-Nel catheter at a dose of 24 μg (50 ml) / day (72 μg / kg) for 4 weeks once a day.

(4) Treatment with hot spring water and ciprofloxacin (n = 8): Ciprofloxacin 2.5 mg and 24 μg (50 ml) / day (72 μg / kg) For 4 weeks.

Example  4. Microbiological tests

In the culture of the bacteria, the weight of the prostate tissue collected from each experimental animal was weighed, cut into a cube shape, and ultrasonicated in 10 ml of PBS for 15 minutes. Ultrasonically treated tissue was cultured quantitatively using a pour plate technique and diluted 10-fold in PBS. 100 μL of a 10-fold step-wise homogeneous suspension and 100 μL of urine were applied to a MacConkey agar culture plate and incubated at 37 ° C. for 24 hours. The number of colonies was then expressed as CFU per gram of prostate tissue and per microliter of urine.

Example  5. Histological examination

Randomly selected abdominal prostate specimens from each group were fixed in 10% buffered formalin, formatted in paraffin, and cut to a thickness of 5 μm. Then, the cells were stained with hematoxylin and eosin staining solution and observed with an optical microscope. Two pathologists who were unaware of the experimental group described the degree of chronic bacterial prostatitis according to three criteria: chronic inflammatory cell infiltration, fibrin change, and interstitial fibrosis. There was no evidence of chronic bacterial prostatitis according to the degree of each item. There was no evidence of chronic bacterial prostatitis at 1 point, 1 point at 10-25%, 2 points at 25-25%, 3 points at 25-50%, 75-100% at 4 points at 50-75% Five points were recorded to describe the degree of prostatitis.

Severity score Inflammatory cell infiltration Fleshy change Interstitial fibrosis 0 No evidence No evidence No evidence One <10% <10% <10% 2 10-25% 10-25% 10-25% 3 25-50% 25-50% 25-50% 4 50-75% 50-75% 50-75% 5 75-100% 75-100% 75-100%

Example  6. Statistical Analysis

All experimental data were expressed as mean ± SD. Infection rates and bacterial counts were analyzed using Pearson's chi-square test and ANOVA. To confirm the results, we conducted a post hoc test. The p value <0.05 was considered statistically significant.

Experiment result

1. Microbiological analysis of prostate tissue and urine culture

The prostate tissue culture and statistical analysis showed statistically significant decrease in bacterial counts compared to the control group (p <0.05) in both hot spring water and ciprofloxacin plus ciprofloxacin alone. Compared with the combination of hot spring water and ciprofloxacin plus ciprofloxacin alone, there was a statistically significant decrease in bacterial counts (p <0.05). The effect of reducing the number of bacteria in the hot spring water alone group compared to the control group was also confirmed.

Urine culture and statistical analysis showed statistically significant decrease in bacterial counts compared to the control group (p <0.05) in both hot spring water and ciprofloxacin plus ciprofloxacin alone. In addition, when the hot spring water and the ciprofloxacin combination group and the ciprofloxacin alone group were compared, there was a statistically significant decrease in the bacterial count in the combination administration group (p <0.05). The effect of reducing the number of bacteria in the hot spring water alone group compared to the control group was also confirmed.

As a result, prostate tissue and urine culture The number of bacteria was significantly lower in the hot spring water and ciprofloxacin-treated groups than in the other groups (Table 3).

group Prostate
Mean (± SD) log ₁₀ CFU / g Urine
Mean (± SD) log ₁₀ CFU / g Control group 6.228 + 0.366 3.394 + 0.283 Ciprofloxacin-treated group 3.391 + 0.275 * 1.700 + 0.269 * Hot spring water treatment group 5.047 ± 0.518 2.719 + - 0.235 Hot spring water and
Group treated with ciprofloxacin 1.962 + 0.344 ** 1.069 + - 0.262 ** *; P <0.05 compared with control group
**; P <0.05 compared with ciprofloxacin group
SD, standard deviation; CFU, colony-forming unit

2. Histological analysis of prostate

E. coli The suspension was injected and 4 weeks later, it was evaluated for chronic inflammatory cell infiltration, fibrin change, and interstitial fibrosis. The severity scores of chronic inflammatory cell infiltration were 4.5 ± 0.5, 2.0 ± 0.5, 3.7 ± 0.4, and 1.5 ± 0.5 in the control, ciprofloxacin, hot spring water, and coadministration groups, respectively. The severity scores of the fibrinous changes were 4.6 ± 0.4, 2.2 ± 0.4, 3.5 ± 0.5, and 1.3 ± 0.4, respectively. The scores of interstitial fibrosis were 4.1 ± 0.3, 2.0 ± 0.5, 3.6 ± 0.4, and 1.3 ± 0.4 One).

Compared with ciprofloxacin alone, ciprofloxacin significantly increased inflammatory cell infiltration, lobular change and interstitial fibrosis compared with ciprofloxacin alone (p <0.05). The hot spring water alone group also showed an effect of improving the infiltration of inflammatory cells, the degree of fibrillar change and the degree of interstitial fibrosis in comparison with the control group (FIGS. 1 and 2).

Claims (13)

A pharmaceutical composition for the prevention or treatment of bacterial prostatitis including hot spring water.
[Claim 2] The pharmaceutical composition according to claim 1, wherein the hot spring water is marine mineral water taken at 1100 m underground of a hot spring area in coastal monotone region 92-1, Kyejin 3 ridge, Okgye-myeon, Gangneung-si, Gangwon-do.
The method of claim 1, wherein the hot spring water comprises potassium, selenium, lithium, sodium, vanadium, chlorine, calcium, germanium, fluorine, magnesium, manganese, bromine, iron, cobalt, sulfuric acid, zinc, titanium, A pharmaceutical composition.
4. The method of claim 3, wherein the hot spring water is selected from the group consisting of potassium 180 to 230 mg / L, selenium 200 to 500 μg / L, lithium 0.02 to 0.15 mg / L, sodium 7000 to 9500 mg / L, vanadium 65 to 130 μg / L of phosphorus, 900 to 1100 mg / L of magnesium, 10 to 40 占 퐂 / L of manganese, 40 to 1700 mg / L of calcium ions, 0.5 to 2.0 mg / L of germanium, 1.5 to 3.0 mg / L of iron, 1.0 to 3.0 mg / L of iron, 1 to 3.5 mu g / L of cobalt, 3000 to 5000 mg / L of sulfuric acid ions, 3.0 to 10.0 mg / L of zinc, 500 to 950 mu g / RTI ID = 0.0 &gt; mg / L. &Lt; / RTI &gt;
The pharmaceutical composition according to claim 1, wherein the hot spring water is a concentrate obtained by concentration and desalting treatment, and the concentrate contains 0.5 to 50% (v / v) based on the total weight of the composition.
The pharmaceutical composition of claim 1, wherein the bacterial prostatitis is chronic bacterial prostatitis.
A pharmaceutical composition for the prevention or treatment of bacterial prostatitis including hot spring water and ciprofloxacin.
[Claim 2] The pharmaceutical composition according to claim 1, wherein the hot spring water is marine mineral water taken at 1100 m underground of a hot spring area in coastal monotone region 92-1, Kyejin 3 ridge, Okgye-myeon, Gangneung-si, Gangwon-do.
The method of claim 7, wherein the hot spring water comprises potassium, selenium, lithium, sodium, vanadium, chlorine, calcium, germanium, fluorine, magnesium, manganese, bromine, iron, cobalt, sulfuric acid, zinc, titanium, A pharmaceutical composition.
10. The method of claim 9, wherein the hot spring water is selected from the group consisting of potassium 180 to 230 mg / L, selenium 200 to 500 μg / L, lithium 0.02 to 0.15 mg / L, sodium 7000 to 9500 mg / L, vanadium 65 to 130 μg / L of phosphorus, 900 to 1100 mg / L of magnesium, 10 to 40 占 퐂 / L of manganese, 40 to 1700 mg / L of calcium ions, 0.5 to 2.0 mg / L of germanium, 1.5 to 3.0 mg / L of iron, 1.0 to 3.0 mg / L of iron, 1 to 3.5 mu g / L of cobalt, 3000 to 5000 mg / L of sulfuric acid ions, 3.0 to 10.0 mg / L of zinc, 500 to 950 mu g / RTI ID = 0.0 &gt; mg / L. &Lt; / RTI &gt;
[Claim 7] The pharmaceutical composition according to claim 7, wherein the hot spring water is marine mineral water taken from an underground 1100m site of a hot spring area in coastal monotonous area 92-1, Kangjin 3 ridge, Okgye-myeon, Gangneung-
8. The pharmaceutical composition according to claim 7, wherein the hot spring water is a concentrate obtained by desalting and evaporating and concentrating the concentrate at 0.5 to 50% (v / v) based on the total weight of the composition.
8. The pharmaceutical composition of claim 7, wherein the bacterial prostatitis is chronic bacterial prostatitis.

Images